Advanced Cancer Therapeutics Awarded Phase I SBIR Grant to Develop Anti-cancer Drug for Novel Cancer Metabolism Target

Published: Oct 11, 2012

LOUISVILLE, Ky., Oct. 11, 2012 (GLOBE NEWSWIRE) -- Advanced Cancer Therapeutics (ACT), a privately held company dedicated to bringing new anti-cancer therapies to market, announced today that it has been awarded a Phase I Small Business Innovative Research (SBIR) grant in the amount of $158,000 by the National Cancer Institute of the National Institutes of Health (NIH) to support the development of a novel therapeutic agent for brain cancer.

Back to news